LDS/Medical Tests/Mucopolysaccharidosis VI (ARSB) Gene Mutation Analysis

Mucopolysaccharidosis VI (ARSB) Gene Mutation Analysis

Mucopolysaccharidosis VI (MPS VI) or Maroteaux-Lamy syndrome is an autosomal recessive, progressive, lysosomal storage disorder caused by a deficiency of arylsulfatase B. The ARSB gene is located on the long arm of chromosome 5 at position 5q11-13. Arylsulfatase B is a lysosomal enzyme active in the breakdown of glycosaminoglycans (GAGs) such as dermatan sulfate and chondroitin sulfate. Deficiency of the enzyme results in accumulation of GAGs in lysosomes, primarily in skeletal and soft tissues leading to the features of the disorder. MPS VI is clinically heterogeneous but is typically characterized by short stature, dysostosis multiplex, facial dysmorphism, stiff joints, hepatosplenomegaly, corneal clouding, and cardiac defects. Patients with MPS VI usually have normal intelligence. The disorder can be classified on the basis of age of onset, height, and urinary GAG level. The classical form of MPS VI, which is rapidly progressing, occurs before 2 to 3 years of age and display elevated urinary GAG levels (generally >100 μg/mg creatinine). Non‐classical slowly progressing MPS VI occurs later in life with more subtle disease manifestations and may demonstrate slightly elevated (generally <100 μg/mg creatinine) or near normal urinary GAG levels. The exact incidence of MPS VI is unknown, although it is estimated to occur in 1 in 250,000 to 600,000 newborns. Although MPS VI is diagnosed through a combination of clinical findings and demonstration of deficient or absent ASB enzyme activity, detection of pathogenic ARSB variants in the proband and in both parents independently confirms diagnosis.
  • Diagnostic confirmation of mucopolysaccharidosis VI
  • Carrier screening in family members of the affected patient
  • For the prenatal diagnosis of known familial mutation(s) in at-risk pregnancies
Any heterozygous mutation (pathogenic variants) detected will indicate carrier status. Any compound or homozygous mutation will confirm diagnosis.

Negative for mutation or pathogenic variant in ARSB gene (Negative for mutations analyzed)

Sequence analysis by next generation sequencing or bi-directional sequencing. ARSB gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood, skin biopsy, cultured cells.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Urinary glycosaminoglycan (GAG) - Dermatan sulfate, heparan sulfate, arylsulfatase B enzyme activity, mucopolysaccharidosis gene mutation panel by NGS
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Iran J Basic Med Sci. 2018;21: 950-956. [PMID: 30524696]
  • Hum Mutat. 2018;39: 1788-1802. [PMID: 30118150]
  • Appl Clin Genet. 2015;8: 245-55. [PMID: 26586959]
  • Expert Rev Mol Med. 2008; 10: e1. [PMID: 18201392]
  • Mol Genet Metab. 2007;92: 122-30. [PMID: 17643332]
  • Genetics Home Reference. Available: https://ghr.nlm.nih.gov/condition/mucopolysaccharidosis-type-vi#